Jazz Q3 revenue tops $1.05B, raises EPS guidance, affirms 2024 revenue outlook at $4.0-4.1B

Jazz Pharmaceuticals plc

2024-Q3 EPS reported $5.63 revenue$2,980,777,000

Q3 2024 record revenue >$1.05B; key growth drivers (Xywav, Epidiolex, Rylaze) up 14% YoY.
Total 2024 revenue guidance reaffirmed at $4.0-4.1B; oncology revenue guidance lowered to $1.08-1.13B.
GAAP EPS guidance raised to $6.70-8.50; non-GAAP EPS guidance raised to $19.50-20.60.
Xywav added ~400 net patients in Q3; strong sleep performance continues.
Zanidatamab PDUFA Nov 29 for 2L BTC; sNDA for Zepzelca in 1L ES-SCLC planned 1H25.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.